Clinical study of ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 5, Issue 1, 2002, Pages 61-63

  Han, Fucai ^a   Yang, Weihua ^a   Zhu, Haibo ^a   Guo, Qinxiang ^a   Guo, Wei ^a   Zhou, Hua ^a  

^a SHANXI CANCER HOSPITAL   (China)

Author keywords

Chemotherapy; Non small cell lung cancer; Regimen

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA;

ADVANCED CANCER; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; SURVIVAL TIME;

EID: 0036478879     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Supportive care versus supportive care and chemotherapy in a metastatic non-small cell lung cancer: Doses chemotherapy make a difference?
2. Chemotherapeutic options in lung cancer
3. Dose-finding study of paclitaxel plus cisplatin in patients with non-small cell lung cancer
4. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients
5. Neoadjuvant mitomycin C, cisplatin, and infusion vinblastine in locally and regionally advanced non-small cell lung cancer: Problems and progress from the perspective of long term follow-up